Biotron's Phenomenal Success ..., page-121

670+ Bullrush.
and that is exactly why patience is required. BIT has to battle its way through the throng of developments targeting COVID.

The only way to do that is what they are doing. Hard science and comprehensive testing. The news is that they will have something to deliver to the FDA in the first quarter of 2022.
They must deliver on that!

Whether human trials will work is unknown …. But the indications are that it has a reasonably good chance because of good results with genetically modified mice to simulate human reactions, and - and this is a big positive - the human tolerance levels are satisfactorily demonstrated already - and that the class of drugs that has been developed was originally aimed at SARS type viruses and engineered towards a particular protein in that class of viruses and gave good results in lab testing.

So let’s see if the company can have some success with the FDA by the end of March. With years of hopeful patiently waiting and hopefulness from this investor (hopefully not misguided), not a lot of extra patience is required for the half a dozen weeks or so to go, or maybe a little sooner.

Good fortune days to come? I hope so for all the patient ones!

pesa.